Peakdale is keen to foster strategic partnerships with the aim of providing innovative solutions for the most demanding drug discovery requirements.
The Company's innovative chemistry, synthesis expertise and flexible resources, make it an ideal partner to complement and support its customers.
From collaborations on new drug-like compounds for specific targets through the creation of exclusive libraries to proof of principle scale up projects, Peakdale adds value to its customers' drug discovery programmes. The Company recognises the benefits of long-term, synergistic relationships to successful partnering.
RECENT COLLABORATION - MATERIA INC.
Peakdale's most recent collaboration was with US metathesis-based scaffold company Materia Inc., whereby Peakdale and Materia collaborated together to design and develop novel scaffolds for the pharmaceutical and related industries. By combining the expertise of metathesis that Materia have developed through their catalyst technologies, and Peakdale's world class chemistry capabilities the collaboration hoped to bring a number of novel series of compounds to market which will accelerate research in a number of areas.
The initial series was selected by Dr. Ray Fisher (Peakdale's CEO) because of its usefulness in exploring novel drug like space and its suitability to synthesis via metathesis.
At the time of the collaboration announcement Dr. Michael Giardello, Materia's Chief Executive said "Peakdale has demonstrated both strong design and development capabilities as well as considerable insight into the scaffolds of interest to discovery chemists. We are pleased to partner with them to expand metathesis' application in the pharmaceutical industry."
For further information about Materia Inc. please click here